| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016929887 |
| P356 | DOI | 10.1038/SJ.ONC.1201857 |
| P698 | PubMed publication ID | 9671396 |
| P2093 | author name string | Deb S | |
| Ludes-Meyers JH | |||
| Lányi A | |||
| Subler MA | |||
| Deb D | |||
| Seymour RC | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| P304 | page(s) | 3169-3176 | |
| P577 | publication date | 1998-06-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain | |
| P478 | volume | 16 |
| Q38520273 | Activation of insulin-like growth factor II signaling by mutant type p53: physiological implications for potentiation of IGF-II signaling by p53 mutant 249. |
| Q42593919 | Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter |
| Q39276191 | Allele specific gain-of-function activity of p53 mutants in lung cancer cells |
| Q34580489 | Cancer chemoresistance: the relationship between p53 and multidrug transporters |
| Q28143345 | Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants |
| Q35103336 | Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice. |
| Q34409021 | Complementation of two mutant p53: implications for loss of heterozygosity in cancer |
| Q46864790 | Complex functions of mutant p53 alleles from human prostate cancer |
| Q64119694 | Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer |
| Q38112074 | Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme |
| Q74088930 | Distinct pattern of p53 phosphorylation in human tumors |
| Q53356436 | Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development. |
| Q36481940 | Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl |
| Q38830254 | Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells. |
| Q40755915 | Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants |
| Q35051410 | Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population |
| Q34462553 | Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53. |
| Q28345092 | Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis |
| Q43185454 | Modulation of MDR/MRP by wild-type and mutant p53. |
| Q26765746 | Mutant p53 and ETS2, a Tale of Reciprocity |
| Q40788757 | Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. |
| Q38844605 | Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication |
| Q38204111 | Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks |
| Q77932308 | Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy |
| Q46709821 | Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q40265316 | Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. |
| Q38197826 | Mutant p53 in cancer: new functions and therapeutic opportunities |
| Q44573111 | Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase |
| Q35561112 | Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway |
| Q24791476 | Mutant p53 proteins bind DNA in a DNA structure-selective mode |
| Q33737277 | Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators |
| Q28208559 | Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil |
| Q34539978 | P53: an ubiquitous target of anticancer drugs |
| Q36527456 | Posttranslational phosphorylation of mutant p53 protein in tumor development |
| Q39597902 | Resistance of mitochondrial p53 to dominant inhibition |
| Q38161342 | Role of p53 in Cell Death and Human Cancers |
| Q36941044 | Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. |
| Q43718785 | The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis |
| Q40325392 | The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. |
| Q34402080 | The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth |
| Q34290217 | The role of tetramerization in p53 function |
| Q36777349 | Transcription regulation by mutant p53. |
| Q36080368 | Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53. |
| Q28208109 | Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction |
| Q39614332 | Tumor-derived p53 mutants induce NF-kappaB2 gene expression |
| Q40568020 | Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. |
| Q35086367 | Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance |
| Q38345714 | p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. |
| Q39422471 | p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity |
| Q38069463 | p53 mutations in cancer |
| Q40896738 | p73 transcriptional activity increases upon cooperation between its spliced forms |
Search more.